Compass Pathways Ltd has recruited Trevor Mill from Biogen Inc to lead the research and development of its psilocybin therapy for treatment-resistant depression and other projects. At Biogen he was head of global safety and regulatory sciences. Compass has developed a synthetic version of psilocybin which has been shown to be safe in studies of patients with depression.
Prior to Biogen, Mr Mill was head of regulatory strategy at Pfizer Inc. He holds a bachelor of science degree in pharmacy from the University of Portsmouth, UK.
Compass Pathways announced the appointment on 23 June 2020.
Copyright 2020 Evernow Publishing Ltd